Ascletis Pharma Inc

Research Ascletis Pharma Inc (2VJ) on Bullrun: market cap EUR 1.10B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker2VJ
• ExchangeF
• CountryChina
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 1.10B
• Financial periodFY2024
• RevenueEUR 1.28M
• Revenue growth-97.7%
• Net income-EUR 300.94M
• Free cash flow-EUR 343.73M
• Gross margin57.3%

Valuation Snapshot

latest market cap is EUR 1.10B.

About Ascletis Pharma Inc

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis;

Frequently asked questions

What is Ascletis Pharma Inc's market cap?

Ascletis Pharma Inc's market capitalization is EUR 1.10B.

What does Ascletis Pharma Inc do?

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus.